She subsequently experienced one other psoriasis flare over 5 years since the end-of-study visit, during a phase II clinical trial for WHIM syndrome of the chemically distinct small-molecule CXCR4 antagonist mavorixafor (26). Here, CXCR4 is linked to WHIM syndrome.